{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T16:47:01Z","timestamp":1766508421650,"version":"3.48.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science and Technology Program of Guangzhou City, China","award":["2024A03J1004"],"award-info":[{"award-number":["2024A03J1004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-03520-4","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T02:28:15Z","timestamp":1766456895000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pirenzepine exhibits anti-prostate cancer activity and enhances checkpoint inhibitor-based immunotherapy by targeting STING"],"prefix":"10.1186","volume":"30","author":[{"given":"Jinge","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongsheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"issue":"1","key":"3520_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"3520_CR2","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.trecan.2020.04.010","volume":"6","author":"U Swami","year":"2020","unstructured":"Swami U, McFarland TR, Nussenzveig R, Agarwal N. Advanced prostate cancer: treatment advances and future directions. Trends Cancer. 2020;6(8):702\u201315.","journal-title":"Trends Cancer"},{"issue":"11","key":"3520_CR3","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.neo.2020.09.002","volume":"22","author":"JE Vellky","year":"2020","unstructured":"Vellky JE, Ricke WA. Development and prevalence of castration-resistant prostate cancer subtypes. Neoplasia (New York, NY). 2020;22(11):566\u201375.","journal-title":"Neoplasia (New York, NY)"},{"issue":"1","key":"3520_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.eururo.2024.09.008","volume":"87","author":"E Francini","year":"2025","unstructured":"Francini E, Agarwal N, Castro E, Cheng HH, Chi KN, Clarke N, et al. Intensification approaches and treatment sequencing in metastatic castration-resistant prostate cancer: a systematic review. Eur Urol. 2025;87(1):29\u201346.","journal-title":"Eur Urol"},{"issue":"4","key":"3520_CR5","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/MOU.0000000000000779","volume":"30","author":"C G\u00eengu","year":"2020","unstructured":"G\u00eengu C, Heidenreich A, Andre\u015fanu A, Mihancea A, Sinescu I, Baston C. Treatment of the primary in metastatic prostate cancer. Curr Opin Urol. 2020;30(4):566\u201375.","journal-title":"Curr Opin Urol"},{"key":"3520_CR6","doi-asserted-by":"publisher","first-page":"217155","DOI":"10.1016\/j.canlet.2024.217155","volume":"601","author":"D Liu","year":"2024","unstructured":"Liu D, Wang L, Guo Y. Advances in and prospects of immunotherapy for prostate cancer. Cancer Lett. 2024;601:217155.","journal-title":"Cancer Lett"},{"key":"3520_CR7","doi-asserted-by":"publisher","first-page":"1212476","DOI":"10.3389\/fimmu.2023.1212476","volume":"14","author":"R Rui","year":"2023","unstructured":"Rui R, Zhou L, He S. Cancer immunotherapies: advances and bottlenecks. Front Immunol. 2023;14:1212476. https:\/\/doi.org\/10.3389\/fimmu.2023.1212476.","journal-title":"Front Immunol"},{"issue":"1","key":"3520_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022;20(1):44.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"3520_CR9","doi-asserted-by":"publisher","first-page":"2426755","DOI":"10.1080\/07853890.2024.2426755","volume":"57","author":"Z Wu","year":"2025","unstructured":"Wu Z, Zhang J, Li L, Wang Z, Yang C. Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors. Ann Med. 2025;57(1):2426755.","journal-title":"Ann Med"},{"key":"3520_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16173033","author":"M Lopes-Pinto","year":"2024","unstructured":"Lopes-Pinto M, Lacerda-Nobre E, Silva AL, Marques P. Therapeutical usefulness of PD-1\/PD-L1 inhibitors in aggressive or metastatic pituitary tumours. Cancers. 2024. https:\/\/doi.org\/10.3390\/cancers16173033.","journal-title":"Cancers"},{"key":"3520_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26031235","author":"A Strati","year":"2025","unstructured":"Strati A, Adamopoulos C, Kotsantis I, Psyrri A, Lianidou E, Papavassiliou AG. Targeting the PD-1\/PD-L1 signaling pathway for cancer therapy: focus on biomarkers. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26031235.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"3520_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","volume":"38","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2020;38(5):395\u2013405.","journal-title":"J Clin Oncol"},{"issue":"8","key":"3520_CR13","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1093\/annonc\/mdy232","volume":"29","author":"AR Hansen","year":"2018","unstructured":"Hansen AR, Massard C, Ott PA, Haas NB, Lopez JS, Ejadi S, et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol. 2018;29(8):1807\u201313.","journal-title":"Ann Oncol"},{"issue":"2","key":"3520_CR14","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.apsb.2021.07.016","volume":"12","author":"X Zhou","year":"2022","unstructured":"Zhou X, Zou L, Liao H, Luo J, Yang T, Wu J, et al. Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8(+) T cell-mediated ferroptosis in castration-resistant prostate cancer. Acta Pharm Sin B. 2022;12(2):692\u2013707.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"3520_CR15","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","volume":"28","author":"T Powles","year":"2022","unstructured":"Powles T, Yuen KC, Gillessen S, Kadel EE, Rathkopf D, Matsubara N, et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med. 2022;28(1):144\u201353.","journal-title":"Nat Med"},{"issue":"5","key":"3520_CR16","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/17512433.2018.1464388","volume":"11","author":"P Isaacsson Velho","year":"2018","unstructured":"Isaacsson Velho P, Antonarakis ES. PD-1\/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol. 2018;11(5):475\u201386.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"7","key":"3520_CR17","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s00228-021-03162-5","volume":"77","author":"T Suzuki","year":"2021","unstructured":"Suzuki T, Higuchi T, Kagami T, Uotani T, Yamade M, Tani S, et al. Effects of pirenzepine on vonoprazan-induced gastric acid inhibition and hypergastrinemia. Eur J Clin Pharmacol. 2021;77(7):971\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"3520_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2165\/00003495-198530020-00001","volume":"30","author":"AA Carmine","year":"1985","unstructured":"Carmine AA, Brogden RN. Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases. Drugs. 1985;30(2):85\u2013126.","journal-title":"Drugs"},{"issue":"1","key":"3520_CR19","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.intimp.2015.05.032","volume":"29","author":"F Alessandrini","year":"2015","unstructured":"Alessandrini F, Cristofaro I, Di Bari M, Zasso J, Conti L, Tata AM. The activation of M2 muscarinic receptor inhibits cell growth and survival in human glioblastoma cancer stem cells. Int Immunopharmacol. 2015;29(1):105\u20139.","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"3520_CR20","doi-asserted-by":"publisher","first-page":"6754","DOI":"10.1007\/s12035-022-03003-1","volume":"59","author":"F Naznin","year":"2022","unstructured":"Naznin F, Waise TMZ, Fernyhough P. Antagonism of the muscarinic acetylcholine type 1 receptor enhances mitochondrial membrane potential and expression of respiratory chain components via AMPK in human neuroblastoma SH-SY5Y cells and primary neurons. Mol Neurobiol. 2022;59(11):6754\u201370.","journal-title":"Mol Neurobiol"},{"issue":"6","key":"3520_CR21","doi-asserted-by":"publisher","first-page":"608","DOI":"10.4103\/aja.aja_55_18","volume":"20","author":"QQ Yin","year":"2018","unstructured":"Yin QQ, Xu LH, Zhang M, Xu C. Muscarinic acetylcholine receptor M1 mediates prostate cancer cell migration and invasion through hedgehog signaling. Asian J Androl. 2018;20(6):608\u201314.","journal-title":"Asian J Androl"},{"issue":"1","key":"3520_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/CAD.0000000000000432","volume":"28","author":"A Mannan Baig","year":"2017","unstructured":"Mannan Baig A, Khan NA, Effendi V, Rana Z, Ahmad HR, Abbas F. Differential receptor dependencies: expression and significance of muscarinic M1 receptors in the biology of prostate cancer. Anticancer Drugs. 2017;28(1):75\u201387. https:\/\/doi.org\/10.1097\/CAD.0000000000000432.","journal-title":"Anticancer Drugs"},{"issue":"1","key":"3520_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ni.2491","volume":"14","author":"DL Burdette","year":"2013","unstructured":"Burdette DL, Vance RE. STING and the innate immune response to nucleic acids in the cytosol. Nat Immunol. 2013;14(1):19\u201326. https:\/\/doi.org\/10.1038\/ni.2491.","journal-title":"Nat Immunol"},{"issue":"12","key":"3520_CR24","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/s43018-022-00468-w","volume":"3","author":"N Samson","year":"2022","unstructured":"Samson N, Ablasser A. The cGAS-STING pathway and cancer. Nat Cancer. 2022;3(12):1452\u201363. https:\/\/doi.org\/10.1038\/s43018-022-00468-w.","journal-title":"Nat Cancer"},{"issue":"1","key":"3520_CR25","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/s41392-021-00613-4","volume":"6","author":"R Zhang","year":"2021","unstructured":"Zhang R, Kang R, Tang D. The STING1 network regulates autophagy and cell death. Signal Transduct Target Ther. 2021;6(1):208. https:\/\/doi.org\/10.1038\/s41392-021-00613-4.","journal-title":"Signal Transduct Target Ther"},{"key":"3520_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao6047","author":"K McArthur","year":"2018","unstructured":"McArthur K, Whitehead LW, Heddleston JM, Li L, Padman BS, Oorschot V, et al. BAK\/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis. Science. 2018. https:\/\/doi.org\/10.1126\/science.aao6047.","journal-title":"Science"},{"key":"3520_CR27","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201899238","author":"JS Riley","year":"2018","unstructured":"Riley JS, Quarato G, Cloix C, Lopez J, O\u2019Prey J, Pearson M, et al. Mitochondrial inner membrane permeabilisation enables mtDNA release during apoptosis. EMBO J. 2018. https:\/\/doi.org\/10.15252\/embj.201899238.","journal-title":"EMBO J"},{"issue":"8","key":"3520_CR28","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.4049\/jimmunol.1701492","volume":"200","author":"M Brault","year":"2018","unstructured":"Brault M, Olsen TM, Martinez J, Stetson DB, Oberst A. Intracellular nucleic acid sensing triggers necroptosis through synergistic type I IFN and TNF signaling. J Immunol. 2018;200(8):2748\u201356.","journal-title":"J Immunol"},{"issue":"12","key":"3520_CR29","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/s41419-020-03239-6","volume":"11","author":"X Zhang","year":"2020","unstructured":"Zhang X, Wu J, Liu Q, Li X, Li S, Chen J, et al. mtDNA-STING pathway promotes necroptosis-dependent enterocyte injury in intestinal ischemia reperfusion. Cell Death Dis. 2020;11(12):1050. https:\/\/doi.org\/10.1038\/s41419-020-03239-6.","journal-title":"Cell Death Dis"},{"key":"3520_CR30","doi-asserted-by":"publisher","first-page":"101215","DOI":"10.1016\/j.redox.2019.101215","volume":"24","author":"N Li","year":"2019","unstructured":"Li N, Zhou H, Wu H, Wu Q, Duan M, Deng W, et al. STING-IRF3 contributes to lipopolysaccharide-induced cardiac dysfunction, inflammation, apoptosis and pyroptosis by activating NLRP3. Redox Biol. 2019;24:101215.","journal-title":"Redox Biol"},{"issue":"12","key":"3520_CR31","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1084\/jem.20171749","volume":"214","author":"KV Swanson","year":"2017","unstructured":"Swanson KV, Junkins RD, Kurkjian CJ, Holley-Guthrie E, Pendse AA, El Morabiti R, et al. A noncanonical function of cGAMP in inflammasome priming and activation. J Exp Med. 2017;214(12):3611\u201326.","journal-title":"J Exp Med"},{"issue":"3","key":"3520_CR32","doi-asserted-by":"publisher","first-page":"e1008294","DOI":"10.1371\/journal.ppat.1008294","volume":"16","author":"BR Kim","year":"2020","unstructured":"Kim BR, Kim BJ, Kook YH, Kim BJ. Mycobacterium abscessus infection leads to enhanced production of type 1 interferon and NLRP3 inflammasome activation in murine macrophages via mitochondrial oxidative stress. PLoS Pathog. 2020;16(3):e1008294. https:\/\/doi.org\/10.1371\/journal.ppat.1008294.","journal-title":"PLoS Pathog"},{"issue":"7","key":"3520_CR33","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41590-020-0699-0","volume":"21","author":"M Jia","year":"2020","unstructured":"Jia M, Qin D, Zhao C, Chai L, Yu Z, Wang W, et al. Redox homeostasis maintained by GPX4 facilitates STING activation. Nat Immunol. 2020;21(7):727\u201335.","journal-title":"Nat Immunol"},{"issue":"1","key":"3520_CR34","doi-asserted-by":"publisher","first-page":"6339","DOI":"10.1038\/s41467-020-20154-8","volume":"11","author":"E Dai","year":"2020","unstructured":"Dai E, Han L, Liu J, Xie Y, Zeh HJ, Kang R, et al. Ferroptotic damage promotes pancreatic tumorigenesis through a TMEM173\/STING-dependent DNA sensor pathway. Nat Commun. 2020;11(1):6339.","journal-title":"Nat Commun"},{"issue":"2","key":"3520_CR35","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.cell.2019.05.035","volume":"178","author":"C Zierhut","year":"2019","unstructured":"Zierhut C, Yamaguchi N, Paredes M, Luo JD, Carroll T, Funabiki H. The cytoplasmic DNA sensor cGAS promotes mitotic cell death. Cell. 2019;178(2):302-15.e23.","journal-title":"Cell"},{"issue":"1","key":"3520_CR36","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41467-019-13689-y","volume":"11","author":"S Lohard","year":"2020","unstructured":"Lohard S, Bourgeois N, Maillet L, Gautier F, F\u00e9tiveau A, Lasla H, et al. STING-dependent paracriny shapes apoptotic priming of breast tumors in response to anti-mitotic treatment. Nat Commun. 2020;11(1):259.","journal-title":"Nat Commun"},{"issue":"4","key":"3520_CR37","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1021\/acs.nanolett.9b04094","volume":"20","author":"S Chattopadhyay","year":"2020","unstructured":"Chattopadhyay S, Liu YH, Fang ZS, Lin CL, Lin JC, Yao BY, et al. Synthetic immunogenic cell death mediated by intracellular delivery of STING agonist nanoshells enhances anticancer chemo-immunotherapy. Nano Lett. 2020;20(4):2246\u201356.","journal-title":"Nano Lett"},{"issue":"2","key":"3520_CR38","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.immuni.2020.01.014","volume":"52","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Fei M, Zhang G, Liang WC, Lin W, Wu Y, et al. Blockade of the phagocytic receptor MerTK on tumor-associated macrophages enhances P2X7R-dependent STING activation by tumor-derived cGAMP. Immunity. 2020;52(2):357-73.e9.","journal-title":"Immunity"},{"issue":"1","key":"3520_CR39","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-020-01247-w","volume":"19","author":"Y Wang","year":"2020","unstructured":"Wang Y, Luo J, Alu A, Han X, Wei Y, Wei X. cGAS-STING pathway in cancer biotherapy. Mol Cancer. 2020;19(1):136.","journal-title":"Mol Cancer"},{"issue":"7213","key":"3520_CR40","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nature07317","volume":"455","author":"H Ishikawa","year":"2008","unstructured":"Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008;455(7213):674\u20138.","journal-title":"Nature"},{"issue":"1","key":"3520_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1087-y","volume":"18","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, An X, Zhang X, Qiao Y, Zheng T, Li X. STING: a master regulator in the cancer-immunity cycle. Mol Cancer. 2019;18(1):152.","journal-title":"Mol Cancer"},{"key":"3520_CR42","doi-asserted-by":"publisher","first-page":"109304","DOI":"10.1016\/j.intimp.2022.109304","volume":"113","author":"R Huang","year":"2022","unstructured":"Huang R, Ning Q, Zhao J, Zhao X, Zeng L, Yi Y, et al. Targeting STING for cancer immunotherapy: from mechanisms to translation. Int Immunopharmacol. 2022;113:109304.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"3520_CR43","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s41419-024-06685-8","volume":"15","author":"X Li","year":"2024","unstructured":"Li X, Pan YF, Chen YB, Wan QQ, Lin YK, Shang TY, et al. Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma. Cell Death Dis. 2024;15(4):300.","journal-title":"Cell Death Dis"},{"issue":"2","key":"3520_CR44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27\u201331.","journal-title":"J Basic Clin Pharm"},{"issue":"8","key":"3520_CR45","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/ddr.21461","volume":"79","author":"A Nair","year":"2018","unstructured":"Nair A, Morsy MA, Jacob S. Dose translation between laboratory animals and human in preclinical and clinical phases of drug development. Drug Dev Res. 2018;79(8):373\u201382.","journal-title":"Drug Dev Res"},{"issue":"3","key":"3520_CR46","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","volume":"22","author":"S Reagan-Shaw","year":"2008","unstructured":"Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008;22(3):659\u201361.","journal-title":"FASEB J"},{"key":"3520_CR47","first-page":"229","volume":"72","author":"G Bianchi Porro","year":"1982","unstructured":"Bianchi Porro G, Petrillo M. Pirenzepine in the treatment of peptic ulcer disease. Review and commentary. Scand J Gastroenterol Suppl. 1982;72:229\u201336.","journal-title":"Scand J Gastroenterol Suppl"},{"issue":"4","key":"3520_CR48","doi-asserted-by":"publisher","first-page":"108327","DOI":"10.1016\/j.celrep.2020.108327","volume":"33","author":"L Wu","year":"2020","unstructured":"Wu L, Lin W, Liao Q, Wang H, Lin C, Tang L, et al. Calcium channel blocker nifedipine suppresses colorectal cancer progression and immune escape by preventing NFAT2 nuclear translocation. Cell Rep. 2020;33(4):108327.","journal-title":"Cell Rep"},{"issue":"5","key":"3520_CR49","doi-asserted-by":"publisher","first-page":"115572","DOI":"10.1016\/j.celrep.2025.115572","volume":"44","author":"Y Dang","year":"2025","unstructured":"Dang Y, Ma M, Wang Y, Zhao M, Cao Y, Su H, et al. Carvedilol sensitizes chemotherapy by targeting STING to boost anti-tumor immunity. Cell Rep. 2025;44(5):115572.","journal-title":"Cell Rep"},{"issue":"3","key":"3520_CR50","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11912-023-01361-0","volume":"25","author":"JB Hines","year":"2023","unstructured":"Hines JB, Kacew AJ, Sweis RF. The development of STING agonists and emerging results as a cancer immunotherapy. Curr Oncol Rep. 2023;25(3):189\u201399.","journal-title":"Curr Oncol Rep"},{"key":"3520_CR51","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jconrel.2024.05.042","volume":"371","author":"J Yang","year":"2024","unstructured":"Yang J, Luo Z, Ma J, Wang Y, Cheng N. A next-generation STING agonist MSA-2: from mechanism to application. J Controlled Release. 2024;371:273\u201387.","journal-title":"J Controlled Release"},{"key":"3520_CR52","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba6098","author":"BS Pan","year":"2020","unstructured":"Pan BS, Perera SA, Piesvaux JA, Presland JP, Schroeder GK, Cumming JN, et al. An orally available non-nucleotide STING agonist with antitumor activity. Science. 2020. https:\/\/doi.org\/10.1126\/science.aba6098.","journal-title":"Science"},{"key":"3520_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112695","author":"A Amouzegar","year":"2021","unstructured":"Amouzegar A, Chelvanambi M, Filderman JN, Storkus WJ, Luke JJ. STING agonists as cancer therapeutics. Cancers. 2021. https:\/\/doi.org\/10.3390\/cancers13112695.","journal-title":"Cancers"},{"issue":"3","key":"3520_CR54","first-page":"175","volume":"35","author":"M Del Tacca","year":"1989","unstructured":"Del Tacca M, Danesi R, Blandizzi C, Bernardini MC. [A selective antimuscarinic agent: pirenzepine. Review of its pharmacologic and clinical properties]. Minerva Dietol Gastroenterol. 1989;35(3):175\u201389.","journal-title":"Minerva Dietol Gastroenterol"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03520-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03520-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03520-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T15:21:22Z","timestamp":1766503282000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-025-03520-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3520"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03520-4","relation":{},"ISSN":["2047-783X"],"issn-type":[{"type":"electronic","value":"2047-783X"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C57BL\/6c and nude mice were housed and maintained in accordance with the standards of the National Institutes of Health guide for the care and use of laboratory animals (NIH Publications No. 8023, revised 1978). All animal experimental protocols were approved by the Ethics Committee of Guangzhou Medical University (approval number: G2023-826).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1250"}}